Bradley M Lunde

This inventor holds 11 USPTO granted patents and 34 published patent applications, plus 1 CIPO patent and 3 EPO patents. Top assignee: Dragonfly Therapeutics, Inc.. Active years: 2024-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Bradley M Lunde. Retrieved from https://idiyas.com/inventor/bradley-m-lunde

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 11 (Patent Applications = 34)

% Patents Active = 100.0

CIPO Patents = 1 (Patent Applications = 33)

EPO Patents = 3 (Patent Applications = 33)

Average Co-Inventor Count = 6.9

ph-index = 3

Forward Citations = 16(Granted Patents)

Company Filing History:

11 out of 15

Dragonfly Therapeutics, Inc.

patents

Years Active: 2024-2026

Loading Chart...

11 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12760105 - MULTI-SPECIFIC BINDING PROTEINS BINDING BCMA, NKG2D AND CD16 AND METHODS OF USE (2026-10-13),

2. 12384851 - Multi-specific binding proteins that bind BCMA, NKG2D and CD16, and methods of use (2025-08-12),

3. 12384847 - Cancer therapy involving an anti-PD1 antibody and a multi-specific binding protein that binds NKG2D, CD16, and a tumor-associated antigen (2025-08-12),

4. 12378318 - Proteins binding NKG2D, CD16 and a tumor-associated antigen (2025-08-05),

5. 12275791 - Multi-specific binding proteins that bind HER2, NKG2D, and CD16, and methods of use (2025-04-14),

6. 12264200 - Antibody variable domains targeting the NKG2D receptor (2025-04-01),

7. 12215157 - Multi-specific binding proteins that bind CD33, NKG2D, and CD16, and methods of use (2025-02-04),

8. 12129300 - Antibody variable domains targeting the NKG2D receptor (2024-10-29),

9. 11939384 - Antibody variable domains targeting the NKG2D receptor (2024-03-26),

10. 11884733 - Antibody variable domains targeting the NKG2D receptor (2024-01-30),

11. 11884732 - Proteins binding HER2, NKG2D and CD16 (2024-01-30),

Title: The Innovative Contributions of Bradley M. Lunde

Introduction

Bradley M. Lunde is a prominent inventor based in Lebanon, NH (US), known for his significant contributions to the field of cancer therapy. With a total of 10 patents to his name, Lunde has made remarkable strides in developing multi-specific binding proteins that target cancer cells.

Latest Patents

Lunde's latest patents focus on multi-specific binding proteins that bind to B-cell maturation antigen (BCMA), NKG2D, and CD16. These proteins are designed to kill human cancer cells effectively. The patents describe pharmaceutical compositions and therapeutic methods that are particularly useful for treating cancers that express BCMA. The multi-specific binding proteins exhibit high potency and maximum lysis of target cells compared to traditional anti-BCMA monoclonal antibodies. Additionally, Lunde has developed a cancer therapy that combines an anti-PD1 antibody with a multi-specific binding protein that binds to a tumor-associated antigen, NKG2D receptor, and CD16. This combination therapy aims to enhance the effectiveness of cancer treatment.

Career Highlights

Lunde is currently associated with Dragonfly Therapeutics, Inc., where he continues to innovate in the field of cancer research. His work has been instrumental in advancing therapeutic methods that improve patient outcomes in cancer treatment.

Collaborations

Lunde collaborates with notable colleagues such as Gregory P. Chang and Ann F. Cheung, contributing to a dynamic research environment that fosters innovation and discovery.

Conclusion

Bradley M. Lunde's work in developing multi-specific binding proteins represents a significant advancement in cancer therapy. His innovative approach and dedication to research continue to impact the field positively.

Profile summary based on public USPTO records.